Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Inclusion Criteria: 1. Healthy volunteers aged 18 to 75 years on the day of inclusion 2. Participant signed informed consent 3. Residing in Philippines. 4. A participant can be included providing COVID-19 polymerase chain reaction (PCR) test is negative at screening. 5. A participant can be included providing, the participant haven't received any vaccination against COVID-19 in the past, or if the participant had already received any of the following licensed vaccines against COVID-19: Oxford/AstraZeneca; Pfizer/BioNTech; Moderna; or J\&J/Janssen, with the participants last dose received at least 6 months prior the inclusion in this trial. Exclusion Criteria: 1. Participant is pregnant, lactating, or of childbearing potential 2. Participation in the 6 months preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure 3. Receipt of any vaccination against COVID-19 less than 6 months prior to participation in study. 4. Receipt of any vaccine in the three months preceding the first trial vaccination or planned receipt of any vaccine in the 6 months following last trial vaccination. 5. Positive SARS-CoV-2 test in the 4 weeks preceding the first trial vaccination 6. Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months 7. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy 8. Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B natural infection (HBcAb positive serology), or hepatitis C 9. Known systemic hypersensitivity to any of the vaccine components (e.g. gold), or history of a life-threatening reaction to vaccines or to a vaccine containing any of the same substances 10. Current alcohol abuse or drug addiction (reported or suspected) 11. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion 12. Thrombocytopenia or any coagulation disorder 13. Identified as an Investigator or employee of the Investigator or study centre with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study (i.e. in the employment of the clinical trial sites). 14. Refusal to be informed if relevant results concerning the participant's health are revealed